Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Some Indian states warn of vaccine shortage as COVID-19 cases peak

04/07/2021 | 11:38am EDT
Outbreak of the coronavirus disease (COVID-19), in New Delhi

NEW DELHI (Reuters) - India reported a record 115,736 new COVID-19 cases on Wednesday, a 13-fold increase in just over two months, raising pressure on the government to expand its vaccination campaign.

Some states, including hardest-hit Maharashtra and Odisha, have complained of a scarcity of vaccines during a second wave that has forced some centres to turn away people.

Only those aged over 45 are now being immunised in India, the world's biggest vaccine maker, which started its campaign with health and other frontline workers in mid-January.

"Vaccination centres have to close early due to a shortage of supplies," Maharashtra's health minister, Rajesh Tope, told reporters.

Stocks would run out in three days after the daily injection of over 450,000 doses, he said.

Odisha said it had closed nearly half of its immunisation sites due to the shortfall, with supplies left only for two more days.

India's health minister said the complaints, mostly from states not ruled by Prime Minister Narendra Modi's party, were attempts to cover up their failures and spread panic.

"Vaccine supplies are being monitored on a real-time basis, and state governments are being apprised regularly about it," Harsh Vardhan said in a statement.

"Allegations of vaccine shortage are utterly baseless."

To requests from states to widen the immunisation drive to include more adults, he said: "So long as the supply of vaccines remains limited, there is no option but to prioritise."

Maharashtra has for weeks accounted for over half India's daily new cases, which on Monday passed 100,000 for the first time. The government blames the resurgence mainly on crowding and a reluctance to wear masks as shops and offices reopen.

The western state, Delhi, Punjab and Karnataka have in recent days imposed new curbs, including night curfews.

The federal government has refused to impose any national lockdown. The previous one last year devastated the economy and left millions penniless.


India has recorded 12.8 million cases, the most after the United States and Brazil.

Deaths from COVID-19 rose by 630 - the highest in four days - to 166,177, according to health ministry data.

Many states have criticised the government as it has restricted India's immunisation drive to some 400 million of its 1.35 billion people.

It has so far administered 86 million doses, 90% of those the AstraZeneca shot made by the Serum Institute of India. The rest have come from Indian company Bharat Biotech, which has struggled to boost output of its homegrown shot.

Only the United States and China have administered more doses.

But with the contagion accelerating, India is racing to increase immunity. It has delayed exports of large quantities of vaccines, though 64.5 million doses have already been shipped.

"We are supposed to be the pharmacy of the world," said a government official who declined to be named. "What kind of pharmacy is this that cannot provide vaccines to even a small portion of its people?"

(Reporting by Krishna N. Das, Rajendra Jadhav, Rama Venkat, Jatindra Dash, Sanjeev Miglani, Neha Arora, Chandini Monnappa, Nivedita Bhattacharjee and Jartindra Dash; Editing by Shri Navaratnam, Simon Cameron-Moore and Timothy Heritage)

By Krishna N. Das and Rajendra Jadhav

© Reuters 2021
All news about ASTRAZENECA PLC
12:29pTHE LATEST : CDC head warns against surging shots to Michigan
12:08pLONDON STOCK EXCHANGE : FTSE 100 ends lower as miners track lower metal prices; ..
10:25aASTRAZENECA  : Argus Research Downgrades AstraZeneca to Hold From Buy
09:35aASTRAZENECA  : Ireland set to restrict use of AstraZeneca vaccine -RTE
09:33aAustralia Expects Big Delays to Vaccine Rollout
09:02aBulgarian PM reveals price for EU's new vaccine contract with Pfizer
08:54aASTRAZENECA  : Indian panel gives emergency approval for Russia's Sputnik V vacc..
08:35aASTRAZENECA  : Brazil, Mexico, Philippines among those due to get Pfizer shots f..
08:00aSpain expects first batch of single-dose Janssen shot within 48 hours
07:26aEUROPE ECONOMICS : Action Economics on The UK Week Ahead; COVID-19 Vaccine Rollo..
More news
Financials (USD)
Sales 2021 30 893 M - -
Net income 2021 4 586 M - -
Net Debt 2021 14 367 M - -
P/E ratio 2021 27,7x
Yield 2021 2,86%
Capitalization 131 B 131 B -
EV / Sales 2021 4,71x
EV / Sales 2022 4,06x
Nbr of Employees 76 100
Free-Float 95,8%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 130,05 $
Last Close Price 99,88 $
Spread / Highest target 66,2%
Spread / Average Target 30,2%
Spread / Lowest Target -5,71%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC-0.51%131 272
JOHNSON & JOHNSON2.46%424 524
ROCHE HOLDING AG0.21%288 043
PFIZER, INC.-0.57%204 161
NOVARTIS AG-3.29%197 172
MERCK & CO., INC.-6.71%193 164